Blueprint Medicines, a Sanofi Company, Announces Four-Year PIONEER Data Showing Sustained Benefit and Long-Term Safety of AYVAKIT(R) (avapritinib) in Indolent Systemic Mastocytosis

Blueprint Medicines, a Sanofi company, today announced AYVAKIT(R) (avapritinib) data showing clinically meaningful outcomes and a w ...